News

Deal Announcements

Inotek Pharma Clears $19 Million Third Round

Monday, August 27, 2007 5:00:00 AM PDT | VentureDeal Staff
BEVERLY, MA -- Inotek Pharmaceuticals, Inc. said that it has closed its series C round, receiving $19.3 million from existing and new investors.

Inotek has several products in development targeting oncology, cardiovascular and inflammatory diseases.  The company's lead candidate is an oncology therapeutic that is in clinical Phase 1 trials.

Investors were Care Capital, CDP Quebec, MedImmune Ventures, Pitango Venture Capital, Rho Ventures, Hercules Technology Growth Capital, Meditor Capital Management and Mitsubishi UFJ Capital.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1